**Overall survival**

Follow-up for 2 years = 87%

Median FU (Range) = 51 months (0 – 288 months)

|  |
| --- |
| **Case Processing Summary** |
| Total N | N of Events | Censored |
| N | Percent |
| 486 | 15 | 471 | 96.9% |

|  |  |  |
| --- | --- | --- |
| Time (years) | Survival probability | SE |
| 2 | 97.1 | 0.8 |



|  |
| --- |
| **Case Processing Summary** |
| Gal3Cy | Total N | N of Events | Censored |
| N | Percent |
| >40 - 150 | 171 | 12 | 159 | 93.0% |
| >150 | 315 | 3 | 312 | 99.0% |
| Overall | 486 | 15 | 471 | 96.9% |

|  |  |  |  |
| --- | --- | --- | --- |
| Gal3Cy | >40 - 150 | >150 | P-value  |
| Time (years) | Survival probability | SE | Survival probability | SE |  |
| 2 | 93.7 | 1.9 | 99.0 | 0.6 | 0.001\* |



**Disease free survival**

|  |
| --- |
| **Case Processing Summary** |
| Total N | N of Events | Censored |
| N | Percent |
| 486 | 41 | 445 | 91.6% |

|  |  |  |
| --- | --- | --- |
| Time (years) | Survival probability | SE |
| 2 | 94.3 | 1.1 |



|  |
| --- |
| **Case Processing Summary** |
| Gal3Cy | Total N | N of Events | Censored |
| N | Percent |
| >40 - 150 | 171 | 35 | 136 | 79.5% |
| >150 | 315 | 6 | 309 | 98.1% |
| Overall | 486 | 41 | 445 | 91.6% |

|  |  |  |  |
| --- | --- | --- | --- |
| Gal3Cy | >40 - 150 | >150 | P-value  |
| Time (years) | Survival probability | SE | Survival probability | SE |  |
| 2 | 86.1 | 2.7 | 99.0 | 0.6 | 0.001\* |



Univariate analysis-OS

|  |  |  |  |
| --- | --- | --- | --- |
|  | Hazard ratio | 95.0% CI for HR | P-value |
|  |  | Lower | Upper |  |
| Gal3 Cy ( >40 -150 v/s >150) | **7.67** | 2.16 | 27.20 | 0.002\* |

Univariate analysis-DFS

|  |  |  |  |
| --- | --- | --- | --- |
|  | Hazard ratio | 95.0% CI for HR | P-value |
|  |  | Lower | Upper |  |
| Gal3 Cy ( >40 -150 v/s >150) | **11.16** | 4.69 | 26.56 | 0.001\* |